Uncovering the Role of Brain Organoids in Defining Human Uniqueness

100-day-old brain organoids

Madeline Lancaster

Since the inception of brain organoids by Madeline Lancaster in 2013, these structures have become invaluable in global brain research. But what are they really? Are they simply miniaturized brains? Could implanting them into animals yield a super-intelligent mouse? Where do we draw the ethical line? Michael Le Page explored these questions at Lancaster’s lab at the MRC Institute of Molecular Biology in Cambridge, UK.

Michael Le Page: Can you clarify what a brain organoid is? Is it akin to a mini brain?

Madeline Lancaster: Not at all. There are various types of organoids, and they are not miniature brains. We focus on specific parts of the human brain, and our organoids are small and immature. They don’t function like developed human brains with memories. In scale, they’re comparable to insect brains, lacking the necessary tissue present in those brains. I would categorize them closer to insect neural structures.

What motivated you to create your first brain organoid?

I initiated the process using mouse embryonic brain cells, cultivating them in Petri dishes. Some cells didn’t adhere as expected, leading to a fascinating outcome where they interconnected and formed self-organizing cell clusters indicative of early brain tissue development. The same technique was then applied to human embryonic stem cells.

Why is the development of brain organoids considered a significant breakthrough?

The human brain is vital to our identity and remained enigmatic for a long time. Observing a mouse brain doesn’t capture the intricacies of the human brain. Brain organoids have opened a new perspective into this complex system.

Can you provide an example of this research?

One of our initial ventures involved modeling a condition called micropathy, where the brain is undersized. In mice, similar mutations don’t alter brain size. We tested whether we could replicate size reduction in human brain organoids, and we succeeded, enabling further insights into the disease.

Madeline Lancaster in her lab in Cambridge, UK

New Scientist

What has been your most significant takeaway from studying brain organoids?

We are gaining a better understanding of what distinguishes the human brain. I’m fascinated by the finding that human stem cells which generate neurons behave differently from those in mice and chimpanzees. One key difference is that human development is notably slower, allowing for more neurons to be produced as our stem cells proliferate.

Are there practical outcomes from this research?

Much of our foundational biology research has crucial implications for disease treatment. My lab primarily addresses evolutionary questions, particularly genetic variances between humans and chimpanzees. Specific genes that arise are often linked to human disorders, implying that mutations essential for brain development could lead to significant damage.

What types of treatments might emerge from this work in the future?

We’re already utilizing brain organoids for drug screening. I’m especially optimistic about their potential in treating mental health conditions and neurodegenerative diseases, where novel therapies are lacking. Currently, treatments for schizophrenia utilize medications that are five decades old. Brain organoid models could unveil new approaches. In the longer term, organoids might even provide therapeutic options themselves. While not for all brain areas, techniques have already been developed to create organoids of dopaminergic neurons from the substantia nigra, which are lost in Parkinson’s, for potential implantation.

Are human brain organoids already being implanted in animal brains?

Yes, but not for treatment purposes; rather, these practices enhance human organoid research. Organoids usually lack vascularity and other cell types from outside the brain, especially microglia, which serve as the brain’s immune cells. Thus, to examine how these other cells interact with human brain matter, various studies have implanted organoids into mice.

Should we have concerns regarding the implantation of human organoids in animals?

Neurons are designed to connect with one another. So, when a human brain organoid is inserted into a mouse brain, the human cells will bond with mouse neurons. However, they aren’t structured coherently. These mice exhibit diminished cognitive performance after implantation, akin to a brain malfunction; hence, they won’t become super-intelligent.

Images of the color of brain organoids, showing their neural connections

MRC Institute of Molecular Biology

Is cognitive enhancement a possibility?

We’re quite a distance from that. Higher-level concepts relate to how different brain regions interlink, how individual neurons connect, and how collections of neurons communicate. Achieving an organized structure like this could be possible, but challenges like timing persist. While mice have a short lifespan of about two years, human development toward advanced intelligence takes significantly longer. Furthermore, the sheer size of human brains presents challenges; a human-sized brain cannot fit within a mouse. Because of these factors, I don’t foresee such concerns emerging in the near future.

Regarding size, the main limitation is the absence of blood vessels. Organoids start to die off when they exceed a few millimeters. How much headway has been made in addressing this issue?

While we’ve made strides and should acknowledge our accomplishments, generating brain tissue is relatively straightforward as it tends to develop autonomously. Vascularization, however, is complex. Progress is being made with the introduction of vascular cells, but achieving fully functional blood perfusion remains a significant hurdle.

When you reference ‘far away’…

I estimate it could take decades. It may seem simple, given that the body accomplishes this naturally. However, the challenges arise from the body’s integrated functioning. Successfully vascularizing organoids requires interaction with a whole organism; we can’t replicate this on a plate.

If we achieve that, could we potentially create a full-sized brain?

Even if we manage to develop a large, vascularized human brain in a lab, without communication or sensory input, it would lack meaningful function. For instance, if an animal’s eyes are shut during development and opened later, they may appear functional, but the brain can’t interpret visual input, rendering it effectively blind. This principle applies to all senses and interactions with the world. I believe that an organism’s body must have sensory experiences to develop awareness. Certain patients who lose sensory input can end up experiencing lock-in syndrome, an alarming condition. But these are individuals who have previously engaged with the world. A brain that has never engaged lacks context.

As brain organoid technology progresses, how should we define the boundaries of ethical research?

The field closely intersects with our understanding of consciousness, which is complex and difficult to measure. I’m not even certain I have the definitive answer about consciousness for myself. However, we can undoubtedly assess factors relevant to consciousness, like organization, sensory inputs and outputs, maturity, and size. Mice might meet several of these criteria but are generally not recognized to possess human-like consciousness, largely due to their size. Even fully interconnected human organoids won’t achieve human-level consciousness if they remain small. Establishing these kinds of standards offers more practical methods than attempting to directly measure consciousness.

https://www.youtube.com/watch?v=xa82-7txy50

topic:

Source: www.newscientist.com

Vascular Organoids Rapidly Repair Injured Tissue

Human vascular organoids created from stem cells

Melero Martin Lab at Boston Children’s Hospital

A new method using small, lab-grown vascular structures has effectively restored blood flow to injured tissue in mice, significantly reducing necrosis. This technique shows promise for mitigating damage caused by injuries or blood clots in the future.

Previously, researchers developed vascular organoids by immersing human stem cells in a mix of chemicals, a process that took weeks and often resulted in structures that did not accurately replicate natural blood vessels, according to Juan Melero-Martin from Harvard University.

In a new approach, Melero-Martin and his team genetically modified human stem cells derived from reprogrammed skin cells. By introducing a genetic sequence and the antibiotic doxycycline, they were able to create vascular organoids in just five days. “The resulting blood vessels exhibited protein and gene activity levels closely resembling those of natural human tissues,” notes Melero-Martin.

To evaluate the organoids’ ability to rehabilitate damaged tissue, the researchers surgically obstructed the blood supply to one leg of several mice, reducing blood flow to less than 10% of normal. After an hour, they introduced 1,000 organoids at the injury site.

Two weeks post-implantation, imaging revealed that the new blood vessels had integrated with the existing ones, restoring blood flow to approximately 50% of normal levels, as stated by Oscar Abiles at Stanford University. “In cases of heart attacks, restoring even this amount of blood flow can significantly minimize tissue damage.”

Post-treatment, about 75% of the mice exhibited minimal dead tissue, while in a control group without organoid treatment, nearly 90% experienced severe tissue death.

In additional trials, the team treated mice with type 1 diabetes with organoids, which had caused pancreatic damage and elevated blood glucose levels. They discovered that integrating organoids with pancreatic tissue transplantation greatly enhanced glycemic control compared to transplantation alone.

However, further studies involving larger animals such as pigs are essential before considering human trials, Abirez states. Melero-Martin anticipates that human research could begin within five years.

Besides facilitating tissue repair, these findings may lead to the development of lab-grown mini-organs that more accurately represent bodily functions or even mini-tumors for research and treatment testing.

“Until recently, organoids lacked blood vessels and could only grow to a limited size. Beyond a few millimeters, they began to perish,” explains Abirez. “This study offers a method to incorporate blood vessels into organoids, thus enhancing their fidelity to human physiology and aiding treatment development.”

topic:

Source: www.newscientist.com

Uterine fluid-based organoids show promise for treating unborn fetuses

A ball of cells grown from amniotic fluid. Red indicates lung stem cells

Giuseppe Cara, Paolo di Coppi, Mattia Guerli

Babies born with serious medical conditions may one day receive better diagnosis and treatment in utero, thanks to a new technique that takes samples of cells from intrauterine fluid and grows them in dishes. It might become.

world's first, paolo de coppi Researchers at Great Ormond Street Hospital in London have shown that fetal cells from amniotic fluid can be induced to form miniature spheres of lung, kidney or small intestine tissue. They also showed that these lung organoids could help treat babies born with a sometimes fatal lung disease called congenital diaphragmatic hernia (CDH).

Although the technique has not yet been used to treat children, the results show it is possible in principle, De Coppi said. The strategy, which researchers call “personalized prenatal medicine,” can also be modified to help treat a variety of other congenital conditions.

The idea takes advantage of a recent approach in which cells in a dish are induced to grow into lentil-sized tissue organoids that take on a three-dimensional structure. These are better than standard techniques of growing cells in two-dimensional layers to capture specific aspects of the tissue in question, such as whether the tissue is healthy or growing abnormally.

The researchers now show that samples of amniotic fluid taken during pregnancy contain fetal cells that can form tissue organoids for the lungs, kidneys, and small intestine.

Studying organoids made from cells from fetuses known to suffer from congenital disorders can tell doctors exactly what form they take, how severe they are, and how they can be treated. We may be able to provide further information.

The researchers created organoids for 12 fetuses with CDH, which causes abdominal organs to push up into the chest, preventing the left lung from growing properly. This condition can be treated by pushing a balloon into the baby's lungs while the baby is in the womb to expand the lungs and improve growth.

The researchers created lung organoids from the fetuses before and after balloon treatment. They found hints that the organoids created after the treatment behaved more like healthy lung tissue than those created beforehand, suggesting that the treatment was successful.

Therefore, organoid technology can be used not only to monitor whether a treatment is effective, as doctors perform this intervention only in the most severe cases, but also to determine whether treatment is needed in the first place. You can use it.

“This has great potential for functional diagnostics,” says De Coppi. “We know how to make diagnoses based on images, but sometimes there are extensive diagnoses. [condition severity] Possible. We want to provide better prenatal diagnostic tools. ”

“If we can classify a disease as mild, moderate, or severe, that's a huge accomplishment,” he says. Cecilia Goeterstrom At Karolinska Institutet, Stockholm, Sweden.

holm schneider Researchers at Germany's Erlangen University Hospital say their approach suggests that organoids could one day be converted into mature tissue and transplanted into babies after birth, even if part of their intestine is missing, for example. ing. “If we could engineer gut-like structures for these children to use after birth, we would be in a much better position,” he says.

topic:

Source: www.newscientist.com